Market Place
Sourcing Support
Enanta Pharma Announces Sale of a Portion of Global Royalties on MAVYRET
25 Apr 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Study of EDP-323
17 Oct 2022 //
BUSINESSWIRE
EU Marketing Authorisation change for Maviret
09 Mar 2020 //
PHARMA TIMES
AbbVie gets positive CHMP opinion for Maviret to shorten treatment
03 Feb 2020 //
PHARMABIZ
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir)
31 Jan 2020 //
PR NEWSWIRE
FDA clears shorter treatment regimen for AbbVie`s hep C treatment
30 Sep 2019 //
ENDPTS
AbbVie’s HCV treatment receives first for shorter treatment cycle
30 Sep 2019 //
IN-PHARMATECHNOLOGIST
US FDA approves AbbVie `s Mavyret to shorten treatment duration
28 Sep 2019 //
PHARMABIZ
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir)
27 Sep 2019 //
PR NEWSWIRE
Gilead’s hep C generics now own more than 20% of market
17 Sep 2019 //
FIERCE PHARMA
FDA issues safety warning for newer hepatitis C drugs following patient deaths
28 Aug 2019 //
BIOPHARMADIVE
FDA approves first treatment for all genotypes of hepatitis C in pediatric
30 Apr 2019 //
PR NEWSWIRE
MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie
13 Mar 2019 //
MSFACCESS
Gilead airs first ads for hep C brand Epclusa
05 Feb 2019 //
FIERCE PHARMA
NHS England sees off AbbVie`s Hep C legal challenge
22 Jan 2019 //
PM LIVE
AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage
13 Dec 2018 //
FIERCE PHARMA
AbbVie`s Mavyret shortens treatment period for some hep C patients
16 Nov 2018 //
FIERCE PHARMA
AbbVie`s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates
15 Nov 2018 //
PR NEWSWIRE
Medicines Patent Pool Signs Licence with AbbVie to Expand Hep-C Glecaprevir
12 Nov 2018 //
PR NEWSWIRE
Gilead`s HIV portfolio soars, but HCV sales falling?
27 Oct 2018 //
FIERCE PHARMA
FDA Issues 54 New and Revised Product-Specific Guidances
13 Sep 2018 //
RAPS
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer
08 Aug 2018 //
FIERCE PHARMA
Epclusa`s fast-tracked Chinese approval might be late for Gilead
31 May 2018 //
FIERCE PHARMA
With hep C still under fire, Gilead`s bottoming out
02 May 2018 //
FIERCE PHARMA
AbbVie blows hep C forecasts out of the water
26 Apr 2018 //
FIERCE PHARMA
AbbVie`s Mavyret takes a big bite from Gilead`s hep C guidance
07 Feb 2018 //
FIERCE PHARMA
AbbVie Demonstrates Leadership in HCV with New MAVYRET™glecaprevir/pibrentasvir
11 Oct 2017 //
PR NEWSWIRE
AbbVie Announces Approval of MAVIRET glecaprevir/pibrentasvir for Hepatitis C
26 Sep 2017 //
PR NEWSWIRE
AbbVie`s Maviret (glecaprevir / pibrentasvir) Receives Approval In Europe
17 Aug 2017 //
EMA
AbbVie’s pan-genotypic hep C therapy cleared in the US
04 Aug 2017 //
PHARMA TIMES
AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir)
03 Aug 2017 //
PR NEWSWIRE
EU Commission Grants AbbVie`s MAVIRET® (glecaprevir/pibrentasvir) MAH
28 Jul 2017 //
PR NEWSWIRE
